Catégorie : Biotech

MABSILICO

by jbertholdin Biotech, Pharma

MABSILICO

About the company

MAbSilico is the TechBio pionner company specializing in computational solutions for discovering and designing therapeutic antibodies. Their solutions leverages artificial intelligence (AI) and machine learning to characterize, optimize and design therapeutic antibodies.

MAbSilico’s platform aims to accelerate the antibody discovery process by structural design with epitope-driven and multiparametric approaches. This allows to design highly effective antibodies, saving time and resources compared to traditional methods. We provide fully characterized antibodies against a target within 21 days that are internally validated with wet lab assays, leading to faster development of life-saving antibody therapies.

About the solution

MAbSilico uses a combination of 3D modeling, interaction simulation, and sequence analysis to identify promising antibody candidates after assessing for various factors, including their binding target (epitope), affinity, potential off-target effects, and developability.

While the solutions can be applied to antibody characterization, optimization and design, MAbSilico does not need to generate biological data to apply their solutions.

Integrating multi-parameters for the antibody design and validating the newly sequence with state of the art biological assays, MAbSilico is pioneering a game-changing approach to antibody discovery with internal discovery pipeline.

Website
Key information

–  Therapeutic areas: Computational antibody design & discovery applied in oncology, Immuno-oncology, Infectious diseases, Rare diseases

–  Based in: Tours & Paris (FRANCE)

–  Employees: 11 – 50

–  Created in: 2017

4P-PHARMA

by jbertholdin Biotech, Pharma

4P-PHARMA

About the company

4P-Pharma is a clinical stage company dedicated to regenerate active drugs to develop first-in-class therapies to cure untreated serious diseases.

They aim to evaluate innovative programs with strong scientific rationale, sourced from the top academic research labs and AI tech companies.

Driven by a vision to pair disease biology of unmet pathologies with drug mechanism of action, their key differentiation is their dual leverage of in-house R&D capabilities located within the Pasteur Institute of Lille, combined with Single Product Vehicle (SPV)-based deployment in charge of advancing the assets through accelerated clinical development to market approvals and distribution agreements by geographic and therapeutic area.

About the solution

Since 2014, the team has reviewed more than 400 projects from different sources of innovation, more then 30 entered in their laboratories for a technical due diligence and 2 have been selected for clinical development.

Two SPVs have been launched:

–  4Living Biotech dedicated to the clinical development of 4P021, a first-in-class treatment for acute respiratory distress syndrome (ARDS) and pulmonary complications.

    –  4Moving Biotech dedicated to the clinical development of 4P004, a first-in-class disease modifying treatment for osteoarthritis.

    Website
    Key information

    –  Therapeutic areas: Chronic and autoimmune diseases, Respiratory and infectious diseases, Preventive therapies, Ophtalmological diseases

    –  Based in: Lille & Paris (FRANCE)

    –  Employees: 11 – 50

    –  Created in: 2014

    BRENUS PHARMA

    by jbertholdin Biotech, Pharma

    BRENUS PHARMA

    About the company

    Despite therapeutic advancements, fighting cancer requires new allies. Cancer cells can adapt themselves under therapeutic pressure and express tumor antigens that hide from our immune system’s surveillance. This mechanism leads to treatment failure of 90% of patients with solid tumors (16 million in 2022).

    Brenus Pharma is a French clinical-stage biotech developing a pioneering discovery platform Stimulated-Tumor-Cell (STC) leading the path of a new generation of immunotherapies. STC doesn’t just fight cancer as it is today; it anticipates how cancer will evolve tomorrow, training the patient’s immune system to recognize and destroy tumors, even as they change.

    Brenus Pharma is on the brink of a breakthrough and will start its First in Human study in 2024 in colorectal cancer, killing 9.7 million of patient per year.
    They are building a strong portfolio in solid tumors, leveraging our patented STC platform, and surpassing other approaches to change a paradigm in oncology.

    About the solution

    The STC Platform mimics patient’s relapsing conditions in vitro to produce next-generation immunotherapies educating patient’s immune system against tumor evolution and mechanisms of relapse.

    Thanks to their unique mode of production, the STCs will educate the immune system to the largest number of specific targets of interest, validated with multi-omics analysis and patient’s biopsies databases. Thanks to the standardization of the platform, access to the drug will not be limited by production or price, and they can also anticipate synergies with other innovations (ADC, ICP).

    Their first candidate, STC-1010, is focused on metastatic colorectal cancer (mCRC) an urgent unmet need.

    Website
    Key information

    –  Therapeutic areas: Primary TA: Metastatic Colo Rectal Cancer (mCRC)
    Secondary TA : Pancreas Cancer, Liver cancer, Ovarian Cancer, Solid Tumors

    –  Based in: Lyon & Clermont-Ferrand (FRANCE)

    –  Employees: 11 – 50

    –  Created in: 2020

    PHOST’IN THERAPEUTICS

    by jbertholdin Biotech, Pharma

    PHOST’IN THERAPEUTICS

    About the company

    Phost’in develops First-in-Class N-glycosylation inhibitors for the treatment of cancers and fibrosis (First-in-Human currently on-going in Europe for the first program).

    About the solution

    PhOx430, First-In-Class selective GnT-V inhibitor, now evaluated in Ph.I in patients with Advance Solid Tumors.

    Website
    Key information

    –  Therapeutic areas: Oncology, Fibrosis

    –  Based in: Montpellier (FRANCE)

    –  Employees: 1-10

    –  Created in: 2014

    TEMISIS

    by jbertholdin Biotech, Pharma

    TEMISIS

    About the company

    Temisis, a preclinical-stage biotechnology company, is developing innovative therapeutics for patients living with chronic inflammatory and auto-immune diseases, with a primary focus on psoriasis. Temisis’ lead drug candidate, TEM2085, is a first-in-class oral small molecule targeting NFKBIZ signaling, which is a key pro-inflammatory gene involved in the pathogenesis of a variety of immunological indications.

    They believe that TEM2085, exhibiting significant efficacy in animal models of immuno-inflammatory diseases and resulting from our drug discovery platform, has the potential to show comparable efficacy to biologics which have demonstrated to date the greatest therapeutic benefit in this area. Temisis’ short-term goal is to move TEM2085 through final stages of preclinical development for clinical evaluation.

    About the solution

    Temisis’ lead drug candidate, TEM2085, is a first-in-class oral small molecule targeting NFKBIZ signaling, which is a key pro-inflammatory gene involved in the pathogenesis of a variety of immunological indications. In vitro, TEM2085 shows, at low concentrations, significant inhibition of NFKBIZ expression induced by IL-17/TNFα in keratinocytes. In vivo, TEM2085 has demonstrated in rodent models, at a lower dose, greater therapeutic benefit than the TYK2 inhibitor deucravacitinib against psoriasis and strong protection against ulcerative colitis. By targeting NFKBIZ signaling, TEM2085 and its analogues have the potential to address various immunological disorders.

    Website
    Key information

    –  Therapeutic areas: Inflammatory diseases, Auto-immune diseases

    –  Based in: Vandœuvre-lès-Nancy (FRANCE)

    –  Employees: 1-10

    –  Created in: 2017

    PRODUCT LIFE GROUP

    by jbertholdin Biotech, Pharma

    PRODUCT LIFE GROUP

    About the company

    PLG provides Product Development consulting services covering:

    – Regulatory science and global development strategy (incl. consultations with agencies)

    – Full CMC development and related QA & QP services (incl. interaction with CDMOs, EU batch certification and release)

    – Nonclinical development strategy consulting & operational support

    – Clinical development strategy consulting & operational support

    – Market access at global and local level

    – Regulatory procedures and documents: briefing packages, ERA, PDE, ODD, PIP, biowaivers CCDS / CCSI…

    – Medical writing & publishing: IND / CTA, (A)NDA / BLA, all eCTD modules, study reports

    – Clinical trials applications management

    – Marketing Authorization procedures management (EU CP / DCP / MRP, US NDA / BLA)

    About the solution

    The team offers flexible consulting approach tailored to Biotechs regulatory needs and works in close collaboration with their partners. Their global network of senior regulatory & CMC experts allows to support all modalities, therapeutic areas and interact with all major regulatory agencies.

    Website
    Key information

    –  Therapeutic areas: Consulting services covering all therapeutic areas and drug modalities

    –  Based in: Headquarter in Courbevoie (FRANCE) DSI Harleysville (US Affiliate)

    –  Employees: 500+

    –  Created in: 1993

    ANTABIO

    by jbertholdin Biotech, Pharma

    ANTABIO

    About the company

    Antabio is a privately-held clinical stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments of drug-resistant infections due to WHO critical priority pathogens, with a particular focus on life-threatening respiratory infections.

    Antabio has one of the best teams in the industry featuring former management and executives from Novexel, GSK, Merck and AstraZeneca with track-records in anti-infective drug development, licensing and M&A. The company has an impressive track-record in attracting non-dilutive funding, including multi-million € awards from the Wellcome Trust, CARB-X, the French Government (ARPEGE), and the European Union (EIC Accelerator).

    About the solution

    Antabio’s portfolio includes MEM-ANT3310, which combines the well-known carbapenem meropenem (MEM) with ANT3310, Antabio’s breakthrough serine-beta-lactamase (SBL) inhibitor. MEM-ANT3310 provides a unique coverage of priority Gram-negative pathogens frequently encountered in life-threatening infections such as Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP). Phase 1a clinical study has recently been completed.

    Their portfolio also includes ANT3273, a groundbreaking (novel class, novel mode of action) inhaled drug targeting the LasB elastase of Pseudomonas aeruginosa (PA), a key virulence factor associated with increased lung pathology severity and worse outcomes in PA-infected patients, such as bronchiectasis, cystic fibrosis, asthma and COPD.

    Website
    Key information

    –  Therapeutic areas: Infectious diseases, Urinary Tract Infection, Respiratory Tract Infection, Multidrug resistant infection, Bacterial infection, Gram negative bacterium infection, Lung infection, Bacterial Pneumonia, Bronchiectasis, Cystic Fibrosis

    –  Based in: Labège (FRANCE)

    –  Employees: 11 – 50

    –  Created in: 2009

    TRUFFLE CAPITAL

    by jbertholdin Biotech, Pharma

    TRUFFLE CAPITAL

    About the company

    For 20 years, Truffle Capital has been financing innovations, growing and empowering technology leaders in healthcare & finance.

    Website
    Key information

    –  Therapeutic areas: Infectious diseases, oncology, rheumatalogy, joint diseases, Transplants

    –  Based in: Paris (FRANCE)

    –  Employees: 11 – 50

    –  Created in: 2001

    QUBIT PHARMACEUTICALS

    by jbertholdin Biotech, Pharma

    QUBIT PHARMACEUTICALS

    About the company

    Qubit Pharmaceuticals specializes in ‘in silico’ drug discovery for challenging disease targets, including those currently viewed as being ‘undruggable’ using small molecules by the pharmaceutical community.

    Their approach is using proprietary molecular simulation and quantum-physics based modeling technology built from over 30 years of research from Pr. Jay W. Ponder’s lab in Washington University in St. Louis, Pr. Pengyu’s Ren lab in University of Texas at Austin, Pr. Jean-Philip Piquemal and Docteur Louis Lagardère at Sorbonne University, and Pr. Matthieu Montes at the Conservatoire national des arts et métiers (Cnam).

    About the solution

    Qubit Pharma uses a hybrid approach leveraging the power of both classical and quantum computing to produce more effective and safer drugs and is designed to significantly reduce the time and investment needed to discover new drug candidates by a factor of 10.

    Today, the focus lies on solving cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. Qubit Pharma is well positioned to become one of the first companies to show a practical quantum advantage in drug discovery.

    In less than 18 months, Qubit Pharmaceuticals grew its drug discovery portfolio to 6 programs in oncology & inflammation leveraging its proprietary drug discovery platform, Atlas.

    Qubit Pharma out-licenses and co-develops compounds with pharmaceutical partners. Once our candidate compounds have achieved advanced stages of drug development, we may seek out-licensing and other strategic alliances for further development, manufacturing, and launching the drug as a commercial pharmaceutical product in selective geographies.

    Website
    Key information

    –  Therapeutic areas: Solving cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases

    –  Based in: Paris (FRANCE) & Boston (USA)

    –  Employees: 51 – 200

    –  Created in: 2020

    CEVIDRA

    by jbertholdin Biotech, Pharma

    CEVIDRA

    About the company

    Founded 17 years ago, Cevidra is an independent pharmaceutical company with a strong expertise in hospital affairs, particularly in tenders, and a vast network of experts. As a rapidly growing entity in the early access domain, Cevidra acts as a gateway to the French market for foreign companies. Rooted in innovation, agility, and commitment, Cevidra offers comprehensive services from its headquarters in Grasse, with additional offices in Paris and Lyon.

    Holding GDP/GMP certifications, it excels as an « Exploitant » for pharmaceutical products, specializing in distribution through its logistical platform. Cevidra provides services ranging from regulatory affairs to market access and real-world data collection. It has a strong track record in managed access programs across various areas, including ATMPs.

    About the solution

    As an Exploitant with an in-house GDP platform, Cevidra offers flexible support to foreign companies launching medicines in France. They handle compassionate/early access programs, market approval, and distribution, including market access and promotional activities in hospitals and pharmacies. Their tailored approach ensures a seamless entry into the French market.

    Website
    Key information

    –  Therapeutic areas: All therapeutic areas including Oncology, Rare diseases and Addictive medicine.

    –  Based in: Grasse, Lyon and Paris (FRANCE)

    –  Employees: 11 – 50

    –  Created in: 2007